.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
McKesson
AstraZeneca
Express Scripts
Deloitte
Daiichi Sankyo
UBS
Boehringer Ingelheim
Cipla
Moodys

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020222

« Back to Dashboard

NDA 020222 describes COLESTID, which is a drug marketed by Pharmacia And Upjohn and is included in two NDAs. It is available from five suppliers. Additional details are available on the COLESTID profile page.

The generic ingredient in COLESTID is colestipol hydrochloride. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the colestipol hydrochloride profile page.

Summary for 020222

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 020222

Mechanism of ActionBile-acid Binding Activity

Medical Subject Heading (MeSH) Categories for 020222

Suppliers and Packaging for NDA: 020222

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
COLESTID colestipol hydrochloride TABLET;ORAL 020222 NDA Pharmacia and Upjohn Company LLC 0009-0450 0009-0450-03 120 TABLET in 1 BOTTLE (0009-0450-03)
COLESTID colestipol hydrochloride TABLET;ORAL 020222 NDA AUTHORIZED GENERIC Physicians Total Care, Inc. 54868-0610 54868-0610-1 30 TABLET in 1 BOTTLE, PLASTIC (54868-0610-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1GM
Approval Date:Jul 19, 1994TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 020222

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And UpjohnCOLESTIDcolestipol hydrochlorideTABLET;ORAL020222-001Jul 19, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Colorcon
US Army
Merck
Farmers Insurance
Moodys
McKesson
UBS
Chubb
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot